비알코올성 지방간질환의 발병기전에 대한 최신지견

참고문헌 (103)

1. Brunt EM, "Nonalcoholic steatohepatitis: definition and pathology", Semin Liver Dis, 21, pp.3~16 (2001)
2. Browning JD, "Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity", Hepatology, 40, pp.1387~1395 (2004)
3. Day CP, "Natural history of NAFLD: remarkably benign in the absence of cirrhosis", Gastroenterology, 129, pp.375~378 (2005)
4. Ekstedt M, "Long-term follow-up of patients with NAFLD and elevated liver enzymes", Hepatology, 44, pp.865~873 (2006)
5. Fassio E, "Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies", Hepatology, 40, pp.820~826 (2004)
6. Adams LA, "The natural history of nonalcoholic fatty liver disease: a population-based cohort study", Gastroenterology, 129, pp.113~124 (2005)
7. Matteoni CA, "Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
8. Day CP, "Steatohepatitis: a tale of two “hits”?", Gastroenterology, 114, pp.842~845 (1998)
9. Harrison SA, "Nonalcoholic steatohepatitis: what we know in the new millennium", Am J Gastroenterol, 97, pp.2714~2724 (2002)
10. Yamaguchi K, "Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis", Hepatology, 45, pp.1366~1374 (2007)
11. Feldstein AE, "Free fatty acids promote hepatic lipotoxicity by stimulating TNF-alpha expression via a lysosomal pathway", Hepatology, 40, pp.185~194 (2004)
12. Jou J, "Mechanisms of disease progression in nonalcoholic fatty liver disease", Semin Liver Dis, 28, pp.370~379 (2008)
13. Gambino R, "Polymorphism in microsomal triglyceride transfer protein: a link between liver disease and atherogenic postprandial lipid profile in NASH?", Hepatology, 45, pp.1097~1107 (2007)
14. Musso G, "Adiponectin gene polymorphisms modulate acute adiponectin response to dietary fat: possible pathogenetic role in NASH", Hepatology, 47, pp.1167~1177 (2008)
15. Namikawa C, "Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis", J Hepatol, 40, pp.781~786 (2004)
16. Miele L, "The Kruppel-like factor 6 genotype is associated with fibrosis in nonalcoholic fatty liver disease", Gastroenterology, 135, pp.282~291 (2008)
17. Romeo S, "Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease", Nat Genet, 40, pp.1461~1465 (2008)
18. Petersen KF, "Apolipoprotein C3 gene variants in nonalcoholic fatty liver disease", N Engl J Med, 362, pp.1082~1089 (2010)
19. Musso G, "Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis", Hepatology, 37, pp.909~916 (2003)
20. Toshimitsu K, "Dietary habits and nutrient intake in non-alcoholic steatohepatitis", Nutrition, 23, pp.46~52 (2007)
21. Bergheim I, "Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin", J Hepatol, 48, pp.983~992 (2008)
22. Tetri LH, "Neuschwander- Tetri BA. Severe NAFLD with hepatic necroinflammatory changes in mice fed trans fats and a high-fructose corn syrup equivalent", Am J Physiol Gastrointest Liver Physiol, 295, pp.G987~G995 (2008)
23. Suzuki A, "Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease", J Hepatol, 43, pp.1060~1066 (2005)
24. Kechagias S, "Fast-food-based hyper-alimentation can induce rapid and profound elevation of serum alanine aminotransferase in healthy subjects", Gut, 57, pp.649~654 (2008)
25. Barrès R, "Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density", Cell Metab, 10, pp.189~198 (2009)
26. Adams LA, "The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies", J Hepatol, 42, pp.132~138 (2005)
27. Cheung O, "Abnormalities of lipid metabolism in nonalcoholic fatty liver disease", Semin Liver Dis, 28, pp.351~359 (2008)
28. Donnelly KL, "Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease", J Clin Invest, 115, pp.1343~1351 (2005)
29. Puri P, "A lipidomic analysis of nonalcoholic fatty liver disease", Hepatology, 46, pp.1081~1090 (2007)
30. Musso G, "Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD)", Prog Lipid Res, 48, pp.1~26 (2008)
31. Evans RM, "PPARs and the complex journey to obesity", Nat Med, 10, pp.355~361 (2004)
32. Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
33. Gavrilova O, "Liver-specific disruption of PPARgamma in leptin-deficient mice improves fatty liver but aggravates diabetic phenotypes", J Clin Invest, 111, pp.737~747 (2003)
34. Horton JD, "SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver", J Clin Invest, 109, pp.1125~1131 (2002)
35. Iizuka K, "Deficiency of carbohydrate response element-binding protein (ChREBP) reduces lipogenesis as well as glycolysis", Proc Natl Acad Sci U S A, 101, pp.7281~7286 (2004)
36. Dentin R, "Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression", J Biol Chem, 279, pp.20314~20326 (2004)
37. Dentin R, "Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob", ob mice, 2006, pp.55, 2159~2170
38. Schreuder TC, "Nonalcoholic fatty liver disease: an overview of current insights in pathogenesis, diagnosis and treatment", World J Gastroenterol, 14, pp.2474~2486 (2008)
39. Semple RK, "PPAR gamma and human metabolic disease", J Clin Invest, 116, pp.581~589 (2006)
40. Pfutzner A, "Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control", Horm Metab Res, 37, pp.510~515 (2005)
41. Yu S, "Adipocyte-specific gene expression and adipogenic steatosis in the mouse liver due to peroxisome proliferator-activated receptor gamma1 (PPARgamma1) overexpression", J Biol Chem, 278, pp.498~505 (2003)
42. Browning JD, "Molecular mediators of hepatic steatosis and liver injury", J Clin Invest, 114, pp.147~152 (2004)
43. Larter CZ, "Insulin resistance, adiponectin, cytokines in NASH: which is the best target to treat?", J Hepatol, 44, pp.253~261 (2006)
44. Mitro N, "The nuclear receptor LXR is a glucose sensor", Nature, 445, pp.219~223 (2007)
45. Zhou J, "Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis", Gastroenterology, 134, pp.556~567 (2008)
46. Denechaud PD, "Role of ChREBP in hepatic steatosis and insulin resistance", FEBS Lett, 582, pp.68~73 (2008)
47. Ueki K, "Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms", Mol Cell Biol, 24, pp.5434~5446 (2004)
48. Tendler D, "The effect of a low-carbohydrate, ketogenic diet on nonalcoholic fatty liver disease: a pilot study", Dig Dis Sci, 52, pp.589~593 (2007)
49. Ueno T, "Therapeutic effects of restrictra diet and exercise in obese patients with fatty liver", J Hepatol, pp.103~107 (1997)
50. Curat CA, "Macrophages in human visceral adipose tissue: increased accumulation in obesity and a source of resistin and visfatin", Diabetologia, 49, pp.744~747 (2006)
51. Wang Y, "Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans", Clin Chem, 53, pp.34~41 (2007)
52. Petta S, "Non-alcoholic fatty liver disease pathogenesis: the present and the future", Dig Liver Dis, 41, pp.615~625 (2009)
53. van der Poorten D, "Visceral fat: a key mediator of steatohepatitis in metabolic liver disease", Hepatology, 48, pp.449~457 (2008)
54. Ronti T, "The endocrine function of adipose tissue: an update", Clin Endocrinol, 64, pp.355~365 (2006)
55. Le Roith D, "Recent advances in our understanding of insulin action and insulin resistance", Diabetes Car, 24, pp.588~597 (2001)
56. Ferré P, "SREBP-1c transcription factor and lipid homeostasis: clinical perspective", Horm Res, 68, pp.72~82 (2007)
57. Park SH, "Nonalcoholic steatohepatitis: pathogenesis and treatment", Korean J Hepatol, 14, pp.12~27 (2008)
58. Krebs DL, "SOCS: physiological suppressors of cytokine signaling", J Cell Sci, 113, pp.2813~2819 (2000)
59. Kim JK, "Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance", Proc Natl Acad Sci USA, 98, pp.7522~7527 (2001)
60. Sanyal AJ, "Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities", Gastroenterology, 120, pp.1183~1192 (2001)
61. Paradis V, "High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: a potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis", Hepatology, 34, pp.738~744 (2001)
62. Ozcan U, "Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes", Science, 306, pp.457~461 (2004)
63. Svegliati-Baroni G, "Insulin and insulin-like growth factor-1 stimulate proliferation and type I collagen accumulation by human hepatic stellate cells: differential effects on signal transduction pathways", Hepatology, 29, pp.1743~1751 (1999)
64. Marchesini G, "Association of nonalcoholic fatty liver disease with insulin resistance", Am J Med, 107, pp.450~455 (1999)
65. St-Pierre J, "Topology of superoxide production from different sites in the mitochondrial electron transport chain", J Biol Chem, 277, pp.44784~44790 (2002)
66. Du XL, "Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation", Proc Natl Acad Sci U S A, 97, pp.12222~12226 (2000)
67. Perez-Carreras M, "Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis", Hepatology, 38, pp.999~1007 (2003)
68. Bilzer M, "Role of Kupffer cells in host defense and liver disease", Liver Int, 26, pp.1175~1186 (2006)
69. Lefkowitch JH, "Kupffer cell aggregation and perivenular distribution in steatohepatitis", Mod Pathol, 15, pp.699~704 (2002)
70. Huang H, "Sensitivity of mice to lipopolysaccharide is increased by a high saturated fat and cholesterol diet", J Inflamm, 4, pp.22~ (2007)
71. Li Z, "Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease", Hepatology, 37, pp.343~350 (2003)
72. Ma X, "Probiotics improve high fat diet-induced hepatic steatosis and insulin resistance by increasing hepatic NKT cells", J Hepatol, 49, pp.821~830 (2008)
73. Velayudham A, "VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice", Hepatology, 49, pp.989~997 (2009)
74. Miura K, "Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1beta in mice", Gastroenterology, 139, pp.323~334 (2010)
75. Marra F, "Adipokines in liver diseases", Hepatology, 50, pp.957~969 (2009)
76. Kadowaki T, "Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome", J Clin Invest, 116, pp.1784~1792 (2006)
77. Wedemeyer I, "Adiponectin inhibits steatotic CD95", Fas up-regulation by hepatocytes: therapeutic implications for hepatitis C, 2009, pp.50, 140~149
78. Xu A, "The fat-derived horhorhoadiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice", J Clin Invest, 112, pp.91~100 (2003)
79. Hui JM, "Beyond insulin resistance in NASH: TNF-alpha or adiponectin?", Hepatology, 40, pp.46~54 (2004)
80. Bugianesi E, "Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity", J Clin Endocrinol Metab, 90, pp.3498~3504 (2005)
81. Baranova A, "Gene expression of leptin, resistin, and adiponectin in the white adipose tissue of obese patients with non-alcoholic fatty liver disease and insulin resistance", Obes Surg, 16, pp.1118~1125 (2006)
82. Kaser S, "Adiponectin and its receptors in non-alcoholic steatohepatitis", Gut, 54, pp.117~121 (2005)
83. Javor ED, "Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy", Hepatology, 41, pp.753~760 (2005)
84. Park JH, "Insulin resistance in non-alcoholic fatty liver disease", Korean J Hepatol, 12, pp.16~30 (2006)
85. Yang SQ, "Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis", Proc Natl Acad Sci USA, 94, pp.2557~2562 (1997)
86. Saxena NK, "Concomitant activation of the JAK", STAT, PI3K, Cancer Res, pp.2007, 67[DOI]
87. Osei-Hyiaman D, "Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice", J Clin Invest, 118, pp.3160~3169 (2008)
88. Uygun A, "Serum leptin levels in patients with nonalcoholic steatohepatitis", Am J Gastroenterol, 95, pp.3584~3589 (2000)
89. Chitturi S, "Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?", Hepatology, 36, pp.403~409 (2002)
90. Chalasani N, "Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis?", Am J Gastroenterol, 98, pp.2771~2776 (2003)
91. Angulo P, "Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease", J Hepatol, 41, pp.943~949 (2004)
92. Schenk S, "Insulin sensitivity: modulation by nutrients and inflammation", J Clin Invest, 118, pp.2992~3002 (2008)
93. Tafani M, "Cytochrome c-dependent activation of caspase-3 by tumor necrosis factor requires induction of the mitochondrial permeability transition", Am J Pathol, 156, pp.2111~2121 (2000)
94. Wieckowska A, "In vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in nonalcoholic fatty liver disease", Hepatology, 44, pp.27~33 (2006)
95. Shapiro L, "The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor", Curr Biol, 8, pp.335~338 (1998)
96. Kugelmas M, "Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E", Hepatology, 38, pp.413~419 (2003)
97. Pagano C, "Increased serum resistin in nonalcoholic fatty liver disease is related to liver disease severity and not to insulin resistance", J Clin Endocrinol Metab, 91, pp.1081~1086 (2006)
98. Rabe K, "Adipokines and insulin resistance", Mol Med, 14, pp.741~751 (2008)
99. Revollo JR, "Nampt", PBEF, Cell Metab, pp.2007, 6[DOI]
100. Stefan N, "High circulating retinol- binding protein 4 is associated with elevated liver fat but not with total, subcutaneous, visceral, or intramyocellular fat in humans", Diabetes Care, 30, pp.1173~1178 (2007)
101. Feldstein AE, "Diet associated hepatic steatosis sensitizes to Fas mediated liver injury in mice", J Hepatol, 39, pp.978~983 (2003)
102. Feldstein AE, "Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis", Gastroenterology, 125, pp.437~443 (2003)
103. McAvoy NC, "Review: Non-alcoholic fatty liver disease: natural history, pathogenesis and treatment", Br J Diabet Vasc Dis, 6, pp.251~260 (2006)